TY  - JOUR
AU  - Poveda, E
AU  - Hernández-Quero, J
AU  - Pérez-Elías, M J
AU  - Ribas, M A
AU  - Martínez-Madrid, O J
AU  - Flores, J
AU  - Navarro, J
AU  - Gutiérrez, F
AU  - García-Deltoro, M
AU  - Imaz, A
AU  - Ocampo, A
AU  - Artero, A
AU  - Blanco, F
AU  - Bernal, E
AU  - Pasquau, J
AU  - Mínguez-Gallego, C
AU  - Pérez, N
AU  - Aiestaran, A
AU  - García, F
AU  - Paredes, R
AU  - PROTEST study group
PY  - 2016
DO  - 10.1111/hiv.12479
UR  - http://hdl.handle.net/10668/10725
T2  - HIV medicine
AB  - Maraviroc (MVC) is a suitable drug for aviraemic subjects on antiretroviral treatment (ART) developing toxicity. Its prescription requires prior tropism testing. It is unknown if proviral DNA genotypic tropism testing is reliable for guiding MVC...
LA  - en
KW  - Maraviroc
KW  - genotypic tropim
KW  - proviral DNA
KW  - Adult
KW  - CCR5 Receptor Antagonists
KW  - Cyclohexanes
KW  - DNA, Viral
KW  - Female
KW  - Genotype
KW  - Genotyping Techniques
KW  - HIV-1
KW  - Humans
KW  - Maintenance Chemotherapy
KW  - Male
KW  - Maraviroc
KW  - Middle Aged
KW  - Prospective Studies
KW  - Proviruses
KW  - Spain
KW  - Treatment Outcome
KW  - Triazoles
KW  - Viral Tropism
TI  - Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study.
TY  - research article
VL  - 18
ER  -